52.95 +0.24 (0.46%)
Pre-market: 5:02AM EDT
|Bid||0.00 x 2900|
|Ask||0.00 x 1800|
|Day's range||52.43 - 53.10|
|52-week range||46.48 - 64.94|
|Beta (5Y monthly)||0.19|
|PE ratio (TTM)||43.28|
|Forward dividend & yield||1.40 (2.66%)|
|Ex-dividend date||25 Feb 2021|
|1y target est||N/A|
Daiichi Sankyo UK, Limited (hereafter, Daiichi Sankyo) and AstraZeneca UK today welcome the news that the National Institute for Health and Care Excellence (NICE) has recommended Enhertu® (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) as an option for treating HER2 positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies.
AstraZeneca has entered into a collaboration agreement with Massachusetts General Hospital (MGH), leveraging robust data and clinical best practices to create digital health solutions that address today’s most urgent healthcare challenges. Catalyzed by the COVID-19 pandemic and a shared mission to improve care for patients with chronic illness, this novel partnership is focused on creating and clinically validating patient-centric digital health solutions and establishing a new standard of care for chronic illness management outside of a clinical setting.
Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday, March 22, 2021.